Induction of remission in biologic-naive, severe psoriasis and PsA with dual anti-cytokine combination

Rheumatology (Oxford). 2021 Jul 1;60(7):e225-e226. doi: 10.1093/rheumatology/keaa880.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adalimumab / therapeutic use*
  • Adult
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Psoriatic / complications
  • Arthritis, Psoriatic / drug therapy*
  • Biological Products / therapeutic use
  • Dermatologic Agents / therapeutic use*
  • Drug Therapy, Combination
  • Female
  • Humans
  • Psoriasis / complications
  • Psoriasis / drug therapy*
  • Psoriasis / pathology
  • Remission Induction
  • Severity of Illness Index
  • Ustekinumab / therapeutic use*

Substances

  • Antirheumatic Agents
  • Biological Products
  • Dermatologic Agents
  • Ustekinumab
  • Adalimumab